Walleye Capital’s Celldex Therapeutics CLDX Stock Holding History

Walleye Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,900	Closed	-$153K	–	4626
2025 Q3	$153K	Buy	+5,900	New	+$137K	﹤0.01%	3485
2025 Q2	–	Sell	-1,700	Closed	-$30.9K	–	4560
2025 Q1	$30.9K	Buy	+1,700	New	+$38K	﹤0.01%	3947
2024 Q3	–	Sell	-4,400	Closed	-$163K	–	5360
2024 Q2	$163K	Buy	4,400 +1,300	+42%	+$49.1K	﹤0.01%	4443
2024 Q1	$130K	Sell	3,100 -3,700	-54%	-$152K	﹤0.01%	4237
2023 Q4	$270K	Buy	6,800 +3,600	+113%	+$106K	﹤0.01%	3453
2023 Q3	$88.1K	Buy	3,200 +3,000	+1,500%	+$94K	﹤0.01%	3998
2023 Q2	$6.79K	Buy	+200	New	+$6.74K	﹤0.01%	3977
2023 Q1	–	Sell	-300	Closed	-$13.4K	–	3972
2022 Q4	$13.4K	Buy	+300	New	+$10.7K	﹤0.01%	2719

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CLDX Position: Q2 2026 in Review

Walleye Capital sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 8,147 shares — an estimated $258K sold.

Walleye Capital first reported a position in CLDX in Q4 2021 and held it in 12 quarters. The position peaked at $6.71M in Q4 2023. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Walleye Capital reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 8,147 Celldex Therapeutics shares in Q2 2026, an estimated $258K.
Walleye Capital first reported a position in Celldex Therapeutics in Q4 2021 and held it in 12 quarters.
Walleye Capital's Celldex Therapeutics position peaked at $6.71M in Q4 2023.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.